Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.
Immunocore is working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases.
Immunocore was founded in 2008 by Bent Jakobsen and James Noble. The company is headquartered in Abingdon, Oxfordshire, United Kingdom, with offices in Philadelphia, Pennsylvania and Rockville, Maryland.
Immunocore has developed a novel class of TCR bispecific immunotherapies called ImmTA- Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune.
Immunocore leverages its proprietary, flexible, off-the-shelf ImmTAX platform to develop a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.
Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial.
Immunocore's collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly, and the Bill and Melinda Gates Foundation.
Immunocore is backed by Bill & Melinda Gates Foundation, Fidelity Management & Research Company, General Atlantic, CCB International, JDRF T1D Fund, Rock Springs Capital and others. The company raised a $75M Series C round on Jan 11, 2021. This brings Immunocore's total funding to $568.8M to date.